TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04731272: GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

Sponsor: University of Pennsylvania · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT04731272 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04731272 Rescue Dossier →